EORTC endorses reducing bureaucracy in clinical trials!
Medical societies and patient advocates across disciplines call for urgent [...]
EORTC endorses the European Code of Cancer Practice
The European Code of Cancer Practice (The Code), an initiative coordinated [...]
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma GalleryPRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Long-Term Findings From EORTC1325/KEYNOTE-054 Show Adjuvant KEYTRUDA Demonstrated a Sustained [...]
New Data Gives Hope to Small Cell Lung Cancer Patients
About 13% of lung cancer patients have Small Cell Lung [...]
EORTC abstracts selected at ESMO 2020 Virtual Congress
5 EORTC abstracts were selected for ESMO 2020 that will [...]
New Kid on the block in cancer therapy- the tumour microenvironment
By Marie Morfouace, EORTC Clinical Scientist for Translational Research For [...]
GDPR in the scope of clinical research and secondary use of data: EMA discussion paper
By Anastassia Negrouk, Head of International Policy and DPO Prior [...]
PRESS RELEASE: Advocacy Organizations and Professional Societies from Across the Globe Unite on Brain Tumour Patients’ Charter of Rights
Brussels, Belgium (16 July 2020) — Seventy-five organizations from around [...]
COVID19 and its impact on clinical cancer research: the EORTC network experience
By Davi Kaur, Head of Communication, EORTC Twenty-Twenty will be [...]
Impact of COVID-19 crisis on imaging in oncological trials
This month, EORTC Imaging Group published a paper1, in the [...]
